

# Okyo Pharma Limited

05:55 23 Feb 2021

## Market Report: Airline makers and travel firms fly after Boris reveals road map out of lockdown

FTSE 100 rose gently as investors digested Boris Johnson's roadmap to recovery from Covid-19. London's blue-chip index rose by 11 to 6,623, suggesting most of the well-leaked plan was already priced in.

British Airways owner IAG, aeroengine maker Rolls-Royce and aeroengineer Melrose were the best of the risers on renewed hopes for a return to normal soon. Intercontinental Hotels was up for similar reasons even though it posted a US\$280m loss in 2020.

A sharp drop in the price of Bitcoin overnight has cost boss Elon Musk his status as the world's richest man. Bitcoin has dropped 12% over the last 24 hours, a fall that might have been sparked by Musk himself, who tweeted over the weekend that prices of the cryptocurrency and fellow digital token Ethereum "do seem high lol".

HSBC reinstated its dividend even though profits tumbled by more than a third in 2020. The bank also confirmed it would switch investment even more towards Asia in future and away from Europe and the US.

Among the small caps, OKYO Pharma Limited (LON:OKYO) has received a US patent for a potential new type of analgesic. It is being developed to treat symptoms of neuropathic pain and inflammation in the eyes and dry eye disease.

World High Life PLC's (LON:LIFE) (OTCQB:WRHLF) brand Love Hemp Limited has submitted its novel food dossier to the UK's Food Standards Agency. The firm is looking to support the authorities in regulating the CBD market.

Crossword Cybersecurity PLC (LON:CCS) has signed an agreement with the University of Glasgow to create new software to support a privacy risk and compliance project.

**Price:** 8.625

**Market Cap:** £58.01 m

### 1 Year Share Price Graph



March 2020 September 2020 February 2021

### Share Information

**Code:** OKYO

**Listing:** LSE

**52 week High Low**  
19 0.95

**Sector:** Pharma & Biotech

**Website:** okyopharma.com

### Company Synopsis:

OKYO Pharma Limited is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through our collaboration with pioneer scientists in the field.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).